SCHEDULE: Vanguard Group Reports 0% Stake in Collegium Pharma

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Collegium Pharmaceutical Inc. due to an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Collegium Pharmaceutical Inc.
• As of the event date March 13, 2026, The Vanguard Group reports 0.00 shares beneficially owned, representing 0% of Collegium Pharmaceutical Inc.'s Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in accordance with SEC Release No. 34-39538.
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Collegium Pharmaceutical Inc. as the change in Vanguard's reported beneficial ownership to 0% is due to an internal corporate realignment and disaggregated reporting, not a divestment based on the issuer's performance.

Future Outlook

NA

Management Comments

• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how a major institutional investor, The Vanguard Group, reports its holdings. Such internal realignments are not uncommon among large asset managers and typically do not indicate a change in investment strategy or sentiment towards the underlying issuer, Collegium Pharmaceutical Inc., by Vanguard's broader fund complex. Instead, it signifies a shift in reporting responsibility to specific subsidiaries or business divisions.

Stakeholder Impact

• Shareholders and potential investors in Collegium Pharmaceutical Inc. should be aware that The Vanguard Group, Inc. itself no longer reports beneficial ownership, but its underlying subsidiaries or business divisions may still hold shares and will report them separately.
• Investment professionals tracking institutional ownership will need to adjust their data sources to account for Vanguard's disaggregated reporting.

Key Dates

Keywords

Collegium Pharmaceutical Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Corporate Realignment